1. Faculty of Medicine, Lomonosov Moscow State University, Moscow, Russia; OOO “Gene and Cell Therapy”, Moscow, Russia 2. OOO “Gene and Cell Therapy”, Moscow, Russia 3. Faculty of Medicine, Lomonosov Moscow State University, Moscow, Russia; Medical Education and Research Center, Lomonosov Moscow State University, Moscow, Russia 4. Faculty of Medicine, Lomonosov Moscow State University, Moscow, Russia; Faculty of Medicine, Peoples’ Friendship University of Russia, Moscow, Russia 5. Faculty of Medicine, Lomonosov Moscow State University, Moscow, Russia
Regenerative medicine approaches, such as replacement of damaged tissue by ex vivo manufactured constructions or stimulation of endogenous reparative and regenerative processes to treat different diseases, are actively developing. One of the major tools for regenerative medicine are stem and progenitor cells, including multipotent mesenchymal stem/stromal cells (MSC). Because the paracrine action of bioactive factors secreted by MSC is considered as a main mechanism underlying MSC regenerative effects, application of MSC extracellular secreted products could be a promising approach to stimulate tissue regeneration; it also has some advantages compared to the injection of the cells themselves. However, because of the complexity of composition and multiplicity of mechanisms of action distinguished the medicinal products based on bioactive factors secreted by human MSC from the most of pharmaceuticals, it is important to develop the approaches to their standardization and quality control. In the current study, based on the literature data and guidelines as well as on our own experimental results, we provided rationalization for nomenclature and methods of quality control for the complex of extracellular products secreted by human adipose-derived MSC on key indicators, such as “Identification”, “Specific activity” and “Biological safety”. Developed approaches were tested on the samples of conditioned media contained products secreted by MSC isolated from subcutaneous adipose tissue of 30 donors. This strategy for the standardization of innovative medicinal products and biomaterials based on the bioactive extracellular factors secreted by human MSC could be applicable for a wide range of bioactive complex products, produced using the different types of stem and progenitor cells.
Sagaradze G.D., Grigorieva O.A., Efimenko A.Yu., Chaplenko A.A., Suslina S.N., Sysoeva V.Yu., Kalinina N.I., Akopyan Zh.A., Tkachuk V.A. (2015) Therapeutic potential of human mesenchymal stromal cells secreted components: a problem with standartization. Biomeditsinskaya Khimiya, 61(6), 750-759.
Sagaradze G.D. et al. Therapeutic potential of human mesenchymal stromal cells secreted components: a problem with standartization // Biomeditsinskaya Khimiya. - 2015. - V. 61. -N 6. - P. 750-759.
Sagaradze G.D. et al., "Therapeutic potential of human mesenchymal stromal cells secreted components: a problem with standartization." Biomeditsinskaya Khimiya 61.6 (2015): 750-759.
Sagaradze, G. D., Grigorieva, O. A., Efimenko, A. Yu., Chaplenko, A. A., Suslina, S. N., Sysoeva, V. Yu., Kalinina, N. I., Akopyan, Zh. A., Tkachuk, V. A. (2015). Therapeutic potential of human mesenchymal stromal cells secreted components: a problem with standartization. Biomeditsinskaya Khimiya, 61(6), 750-759.
References
Kalinina N.I., Sysoeva V.Yu., Rubina K.A., Parfenova E.V., Tkachuk V.A. (2011) Acta Naturae (russkoyazychnaya versiya), 3(4), 32-39. Scholar google search
Rubina K., Kalinina N., Efimenko A., Lopatina T., Melikhova V., Tsokolaeva Z., Sysoeva V., Tkachuk V., Parfyonova Y. (2009) Tissue Eng. Part A, 15, 2039-2050. CrossRef Scholar google search
Schievenbusch S., Strack I., Scheffler M., Wennhold K., Maurer J., Nischt R., Dienes H.P., Odenthal M. (2009) Biochem. Biophys. Res. Commun., 385, 55-61. CrossRef Scholar google search
Herberts C.A., Kwa M.S.G., Hermsen H.P.H. (2011) J. Transl. Med., 9, 29. Scholar google search
EMA ICH Topic Q 5 D (1997) Quality of Biotechnological Products: Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products / EMA / Eur. Med. Agency. Scholar google search
European Pharmacopoeia 7.0. (2011) Mycoplasma 2.6.7 / European Pharmacopoeia 7.0.Council ofEurope, Strasbourg. Scholar google search
Bacterial Endotoxins / Pyrogens (1985) FDA Inspection Technical Guides. Food and Drug Administration. - 1 c. Scholar google search
Kim H.-S., Choi D.-Y., Yun S.J., Choi S.-M., Kang J.W., Jung J.W., Hwang D., Kim K.P., Kim D.-W. (2012) J. Proteome Res., 11, 839-849. CrossRef Scholar google search
Kalinina N., Kharlampieva D., Loguinova M., Butenko I., Pobeguts O., Efimenko A., Ageeva L., Sharonov G., Ischenko D., Alekseev D. et al. (2015) Stem Cell Res. Ther., 6, 1-12 (in press). Received 02 July 2015. Scholar google search
Efimenko A.Yu., Dzhoyashvili N.A., Starostina E.E., Kalinina N.I., Akchurin R.S., Parfenova E.V. (2012) v: Stvolovye kletki i regenerativnaya meditsina/ Pod red V.A Tkachuka, Izdatel'stvo “Maks-Press”, Moskva, 150-166. Scholar google search
Efimenko A., Dzhoyashvili N., Kalinina N., Kochegura T., Akchurin R., Tkachuk V., Parfenova Ye. (2014) Stem cells translational medicine, 3, 32-41. CrossRef Scholar google search
Mironov A.N. (2012) Rukovodstvo po provedeniyu doklinicheskikh issledovanij lekarstvennykh sredstv. Chast' pervaya / Pod red. A.N. Mironova. – M.: Grif i K. – 944 s. Scholar google search
EMA ICH Topic Q 6 B. (1999) Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products / EMA / Eur. Med. Agency. Scholar google search
Zhao J., Hu L., Liu J., Gong N., Chen L. (2013) Biomed Res. Int., 2013, 1-11. Received 26 July 2013. Scholar google search
